beat·365(中国)娱乐平台官网-最新版App Store

科学研发

科研创新

研发管线

Dorzagliatin

科学研发

Diabetes, Obesity and Metabolism

Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study

了解更多

Diabetes Therapy

Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels

了解更多

Nature Communications

2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

了解更多

Diabetes

Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes

了解更多

Nature Medicine

2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.

了解更多

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

了解更多

Nature Medicine

2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

了解更多

Clinical and Translational Science

2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

了解更多

Global Journal of Obesity, Diabetes and Metabolic Syndrome

2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

了解更多

Diabetes, Obesity and Metabolism

2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection

了解更多

Clinical Pharmacokinetics

2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics

了解更多

Lancet Diabetes Endocrinology

2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?

了解更多

Lancet Diabetes Endocrinology

2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

了解更多

Journal of Diabetes Research

2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus

了解更多

药学进展

2016年第3期《药学进展》：葡萄糖激酶激活剂研究进展

了解更多

药学进展

2016年第3期《药学进展》：21世纪2型糖尿病新药研发策略：明鉴病理因素，改善机体功能

了解更多

Drug Design, Development and Therapy

2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

了解更多

Intractable & Rare Diseases Research

2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities

了解更多

Clinical Pharmacokinetics

2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process

了解更多

Intractable & Rare Diseases Research

2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities

了解更多

關於華領

公司簡介

發展歷程

管理團隊

戰略顧問委員會

高級科學顧問委員會

合作夥伴

媒體中心

科學研發

科研創新

研發管線

Dorzagliatin

mGluR5

公司論文

同行評審出版物

投資者關系

企業管治

財務報告

公告與通函

上市文件

投資者演示文稿

投資者關系聯系人

投資者關系日歷

股票信息

媒體資訊

公司新聞

視頻專區

求賢納仕

企業文化

在招職位

產品

華堂寧®

关注我们

沪公网安备 31011502013809号

搜索